Last Updated : GMT 14:30:44
Arab Today, arab today
Arab Today, arab today

AstraZeneca rejects Pfizer\'s new $106bn takeover bid

Arab Today, arab today

Arab Today, arab today AstraZeneca rejects Pfizer\'s new $106bn takeover bid

London - AFP

British drugs giant AstraZeneca on Friday rejected a sweetened $106-billion takeover bid from US rival Pfizer, hitting out at the "inadequate"offer as it battles to remain independent. The rejection came hours after Pfizer had lifted its informal cash and shares bid to the equivalent of 76 billion euros, as it seeks to strengthen its research in cancer and slash its tax bill. The Viagra maker offered £50 ($84, 61 euros) per AstraZeneca share, higher than the previous bid worth $99 billion. "The financial and other terms described in the (new) proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer," the British group said in a statement. Analysts said Pfizer was now likely to come back with a hostile bid, which however may still not force through a deal. "It seems the main driver behind the deal is the desire of Pfizer to shelter $70 billion of its cash pile from US taxation rules, and that doesn't seem a sufficiently good reason to do a deal if you are AstraZeneca," said CMC chief strategist Michael Hewson. He added: "The Pfizer CEO has talked up the prospects of a deal being good for the creation of new drugs but AstraZeneca already has a healthy pipeline relative to Pfizer, and reducing competition in the pharmaceutical sector seems a funny way to generate growth in new drugs." AstraZeneca attacked the new bid for offering a "large proportion" payable in Pfizer shares, noting also that the combined firm would still seek to establish its corporate and tax residency in England. "Accordingly, the board has rejected the proposal," the London-listed firm added. Pfizer has highlighted the considerable tax advantages from the transaction, which would create a new UK-incorporated holding company. Outlining his company's defence, AstraZeneca chairman Leif Johansson said it "continues to invest significantly in research, development and manufacturing in the UK, Sweden and the US". He added: "We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the board believes will deliver significant value for shareholders. "Pfizer's proposal would dramatically dilute AstraZeneca shareholders' exposure to our unique pipeline and would create risks around its delivery. As such, the board has no hesitation in rejecting the proposal." - Shares down after rejection - AstraZeneca shares traded down 0.35 percent at £47.98 around midday in London. Earlier Friday, Pfizer chief executive Ian Read said "the industrial logic for a combination between Pfizer and AstraZeneca is compelling". He added that the combined company would bring together "powerful and world-leading" research expertise in key areas such as oncology, inflammation, and cardiovascular and metabolic disorders. Read also vowed in a letter to British Prime Minister David Cameron that Pfizer would complete AstraZeneca's proposed research and development facility in Cambridge, southern England, should the deal go ahead. He added that 20 percent of the new group's research and development (R&D) staff would be based in Britain. Read also spoke of the "highly compelling strategic, business and financial rationale for combining" Pfizer with AstraZeneca. "We believe our proposal is responsive to the views of AstraZeneca shareholders and provides a sound basis upon which to arrive at recommendable terms for the combination of our two companies," he added. - Sector awash with deals - Pfizer's tilt at AstraZeneca comes as global pharmaceutical giants are forming sector deals worth billions of dollars to cope with lost revenues from patent expirations and the effects of public cuts on health care spending. The bid for AstraZeneca follows other mega-mergers undertaken by Pfizer, the biggest US drugmaker by revenue. Prior Pfizer takeovers included Warner-Lambert, Pharmacia and Wyeth. The US group said it would look to locate manufacturing operations in Britain and will keep AstraZeneca's commercial manufacturing facilities in Macclesfield, northwestern England. AstraZeneca currently employs more than 50,000 people around the world, including 6,700 in Britain. Pfizer meanwhile has a global workforce of 70,000 staff, of which 2,500 are in Britain.

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

Arab Today, arab today astrazeneca rejects pfizer\s new 106bn takeover bid Arab Today, arab today astrazeneca rejects pfizer\s new 106bn takeover bid


Arab Today, arab today
Arab Today, arab today Adidas Originals ‘reinterpreted’

GMT 14:52 2016 Thursday ,01 December

Adidas Originals ‘reinterpreted’
Arab Today, arab today Holiday magic is everywhere

GMT 13:04 2016 Saturday ,03 December

Holiday magic is everywhere
Arab Today, arab today Paris's matchbox apartments

GMT 10:37 2016 Saturday ,24 September

Paris's matchbox apartments
Arab Today, arab today First buses take Aleppo residents back

GMT 07:33 2016 Monday ,05 December

First buses take Aleppo residents back
Arab Today, arab today What next after landmark

GMT 09:01 2016 Saturday ,03 December

What next after landmark
View News in Arabic - Business: أخبار الشركات
Arab Today, arab today
Arab Today, arab today
Arab Today, arab today Dino-killing crater shows clues

GMT 14:43 2016 Thursday ,24 November

Dino-killing crater shows clues
Arab Today, arab today Dubai Women Establishment delegation

GMT 13:00 2016 Monday ,05 December

Dubai Women Establishment delegation
Arab Today, arab today To battle Japanese whaling fleet

GMT 11:53 2016 Monday ,05 December

To battle Japanese whaling fleet
Arab Today, arab today Pluto's unruly moons

GMT 06:31 2015 Thursday ,04 June

Pluto's unruly moons
Arab Today, arab today Hyundai allows Saudi journalists

GMT 15:14 2016 Thursday ,01 December

Hyundai allows Saudi journalists
Arab Today, arab today Latest Infiniti QX to compete

GMT 13:16 2016 Saturday ,26 November

Latest Infiniti QX to compete
Arab Today, arab today Trump, politics on the mind

GMT 12:58 2016 Friday ,02 December

Trump, politics on the mind
Arab Today, arab today Green groups pressure Spain

GMT 13:01 2016 Thursday ,01 December

Green groups pressure Spain

GMT 11:44 2016 Thursday ,01 December

Austria's race against time

GMT 08:00 2016 Saturday ,03 December

For Yazidi women left behind

GMT 04:15 2016 Thursday ,30 June

World's largest uncut diamond fails

GMT 13:01 2016 Tuesday ,29 November

Car manufacturers to power Europe

GMT 15:59 2015 Wednesday ,27 May

Seoul elevates gardening to high art

GMT 12:39 2016 Saturday ,26 November

Skin patch could help kids

GMT 13:19 2016 Monday ,21 November

New nationalism stoking fears

GMT 13:12 2015 Saturday ,09 May

Sheikh Sultan opens Sharjah Centre

GMT 09:53 2016 Sunday ,15 May

OMEGA official timekeepers
Arab Today, arab today
Arab Today, arab today
 Arab Today Facebook,arab today facebook  Arab Today Twitter,arab today twitter Arab Today Rss,arab today rss  Arab Today Youtube,arab today youtube  Arab Today Youtube,arab today youtube

Powered and Developed by FilmMatters

Copyright © 2016 Arabtoday

Developed by FilmMatters

© 2016 Arabtoday

arabtoday arabtoday arabtoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
arabtoday, Arabtoday, Arabtoday